The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence.
The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the New England Journal of Medicine demonstrated that the addition of ribociclib to Femara improves survival without cancer progression by 44%.
Advanced or metastatic breast cancer refers to cancer that originated in the breast, but has spread to several and/or distant sites in the body. The goals of treatment for metastatic breast cancer are to improve duration of survival while maintaining quality of life.
The majority of breast cancers are referred to as HR+, meaning their cancer is stimulated to grow from exposure to the female hormones estrogen and/or progesterone. These patients are treated with endocrine therapy (sometimes referred to as hormone, or anti-estrogen therapy), which reduces the cancer cells’ exposure to estrogen through varying mechanisms. Endocrine therapy has proven extremely effective in reducing HR-positive cancer growth and spread for extended periods of time.
Ribociclib is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. CDK4/6 inhibition has been shown to overcome or delay resistance to endocrine therapy.
The MONALEESA-2 clinical trial directly compared ribociclib plus Femara to Femara alone as initial treatment of 668 postmenopausal women with HR+, human epidermal growth factor receptor 2 negative advanced breast cancer.
Among patients with measurable disease the overall response rate was 52.7% with ribociclib and Femara compared to only 37.1% with Femara alone. After a median follow-up of 15.3 months, ribociclib was also associated with a significant improvement in time to cancer progression.
Breast cancer experts at the meeting believe that CDK4/6 inhibition with ribociclib and other cyclin-dependent kinase inhibitors will be a game changer in the treatment of advanced breast cancer. The key question is whether doctors should use them in all patients or whether some biomarker could be identified to use them more selectively. Doctors do not know whether 100% of patients will benefit, or less.
Reference: Hortobagyi B, Stemmer S, Burris H, et al. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Proceedings from the annual meeting of the 2016 European Society for Medical Oncology (ESOM). Abstract LBA1_PR. Presented October 8, 2016.
Copyright © 2016 CancerConnect. All Rights Reserved.